Sign inJoin waitlistJoin the waitlist

Alice Mims

Co-Leader, Leukemia and Hematologic Malignancies Research Program · Ohio State University Hospital

Credentials: · · · · · ·

History

Leukemia and Hematologic Malignancies Research Program · Ohio State University Hospital
Present
Hematology Section · Ohio State University Hospital
Present
Ohio State University Hospital
Present

Wake Forest University Baptist Medical Center
2008–2010
Internal Medicine
Ohio State University Hospital
2005–2008
Med Univ of South Carolina Coll of Med
2001–2005

Research

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 359 citations
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Blood · 2020 · 315 citations

JB
John Byrd
55 papers
William Blum
34 papers
James Blachly
30 papers
KL
Karilyn Larkin
28 papers
Sumithira Vasu
24 papers
Uma Borate
23 papers
Alison Walker
21 papers
ES
Eytan Stein
21 papers
Richard Stone
21 papers
Tara Lin
20 papers
Wendy Stock
20 papers
Ross Levine
19 papers

Grants

Dual Targeting of Oncogenic Signaling and Immune Suppression in High-Risk T-ALL
National Cancer Institute · R01
PI · $511.9K · Ohio State University
2026–2031
Pharmacodynamically Directed Targeted Therapy for Leukemia
National Cancer Institute · R01
PI · $1.4M · University of Pittsburgh at Pittsburgh
2025–2030
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML
National Cancer Institute · R01
PI · $2.6M · Ohio State University
2022–2028
STING Activators as Therapy for Cancer
National Cancer Institute · R42
PI · $993.9K · Stinginn, Llc
2020–2026

Clinical trials

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2027
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Principal investigator · Recruiting · Phase 2
Alice Mims
2022–2029
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2020–2022
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 2, Phase 3
Beat AML, LLC
2016–2032